LivaNova (LIVN) And The Narrative Behind Its Undervalued View
LivaNova (LIVN) has drawn investor attention after a recent move in the stock, with returns over the past 3 months and year contrasting with softer daily and weekly performance.
See our latest analysis for LivaNova.
The recent pullback, with a 1-day share price return of 1.85% and a 7-day share price return of 4.54%, sits against stronger momentum. This includes a 90-day share price return of 22.75% and a 1-year total shareholder return of 87.04%, indicating that longer term gains have been much stronger than the latest move suggests.
If you are comparing LivaNova with other healthcare opportunities, this is a good moment to scan the market using a screener focused on 39 healthcare AI stocks
Recent gains and ongoing questions about LivaNova’s long term trajectory leave bulls pointing to growth and an indicated discount to intrinsic value, while bears focus on past share price swings. The key question is which case the valuation work supports next.
Most Popular Narrative: 6.6% Undervalued
LivaNova’s most followed narrative pegs fair value at $84.80, a touch above the last close at $79.21, which puts the focus squarely on the earnings and cash flow assumptions behind that gap.
The company's clinical innovations, including strong, durable VNS study data in epilepsy and depression, launch of disruptive next-generation OSA neurostimulation (p-HGNS), and continued product upgrades (such as the Essenz platform's software upgradability), position LivaNova to capture share from the long-term shift toward minimally invasive, personalized therapies, which can drive pricing power and higher net margins.
Want to see what kind of revenue path and profit margin uplift this narrative is banking on, and how that filters into a higher earnings base and valuation multiple over time? The detailed storyline spells out a specific balance between growth in neuromodulation, cardiopulmonary equipment, and recurring service revenue that underpins the $84.80 fair value.
Result: Fair Value of $84.80 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this LivaNova narrative could be knocked off course if reimbursement pressure crimps pricing power or if neuromodulation and OSA product uptake falls short of expectations.
Find out about the key risks to this LivaNova narrative.
Next Steps
If the mixed sentiment around LivaNova has you thinking, use this moment to review the numbers yourself and decide quickly where you stand. To understand what is driving optimism, take a closer look at the company's 3 key rewards
Looking for more investment ideas beyond LivaNova?
If LivaNova has sharpened your focus, do not stop here. Fresh ideas across sectors can help you build a more rounded watchlist and spot opportunities earlier.
- Target fast movers by reviewing 20 elite penny stocks with strong financials that combine smaller market caps with stronger financial profiles.
- Zero in on potential value opportunities using the 45 high quality undervalued stocks built around quality metrics and pricing signals.
- Strengthen the defensive side of your portfolio with the 9 dividend fortresses focused on higher yields and resilient payouts.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com